Back to Treatments

Treatment

CPX-351 (Liposomal Cytarabine and Daunorubicin)

1
Conditions
43
Trials
1,000
Participants
25%
Average Safety

Condition Evidence

Acute myeloid leukemia

43 trials · 1,000 participants

78% effectiveness · 25% safety
CPX-351 (Liposomal Cytarabine and Daunorubicin) | DFDA